Auxilium boosts urology business with $585M Actient buy

04/30/2013 | Genetic Engineering & Biotechnology News · Reuters

Auxilium Pharmaceuticals agreed to pay $585 million in cash to purchase urology-treatment-maker Actient Holdings. The deal gives Auxilium access to Actient's testosterone replacement therapies and erectile dysfunction drug. The acquisition "creates a leading urology franchise with a diversified product portfolio and sales force leverage that is well positioned for growth of our current portfolio," Auxilium President and CEO Adrian Adams said.

View Full Article in:

Genetic Engineering & Biotechnology News · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX